ArticleOncology and therapy2026

Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England.

Joel Russell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.